Skip to main navigation Skip to search Skip to main content

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Project: Research

Project Details

StatusActive
Effective start/end date06/1/20 → 12/31/28

Funding

  • Eli Lilly and Company: $2,009,557.50